Boundless Bio
BOLD
40 hedge funds and large institutions have $38.3M invested in Boundless Bio in 2026 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 10 increasing their positions, 9 reducing their positions, and 8 closing their positions.
281% more capital inflows, than outflows
Capital inflows: $14.8M | Capital outflows: $3.9M
63% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 8
30.24% more ownership
Funds ownership: 37.87% → 68.11% (+30%)
11% more funds holding
Funds holding: 36 → 40 (+4)
11% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Arch Venture Management
Chicago,
Illinois
|
+$4.15M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
+$3.94M |
| 3 |
ADAR1 Capital Management
Austin,
Texas
|
+$3.03M |
| 4 |
Cormorant Asset Management
Boston,
Massachusetts
|
+$1.54M |
| 5 |
Millennium Management
New York
|
+$583K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$1.84M |
| 2 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$746K |
| 3 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$682K |
| 4 |
Sio Capital Management
New York
|
-$180K |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$176K |
BOLD Hedge Fund Activity: Q2 2026 in Review
40 of the 8,362 institutional investors tracked by Wall St. Rank reported a position in Boundless Bio (BOLD) for Q2 2026, worth a combined $38.3M — up 310% from $9.33M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new BOLD positions and 8 closed out — a net gain of 5 holders — while 10 added to existing stakes and 9 trimmed.
The largest buyer was Arch Venture Management, opening a new position worth an estimated $4.15M. The largest seller was Citadel Advisors, cutting an estimated $1.84M.
- 40 institutional investors held Boundless Bio (BOLD) as of Q2 2026, up from 36 in Q1 2026.
- Funds reported $38.3M of Boundless Bio stock for Q2 2026, up 310% quarter-over-quarter.
- 13 funds opened new Boundless Bio positions in Q2 2026 and 8 closed out, a net change of +5 holders.
- The largest Boundless Bio buyer in Q2 2026 was Arch Venture Management, an estimated $4.15M added.
- The largest Boundless Bio seller in Q2 2026 was Citadel Advisors, an estimated $1.84M sold.
Based on aggregated 13F filings for Q2 2026.